Abstract 14415: GlycA Is Associated With Coronary Artery Calcium Above and Beyond C-reactive Protein. The Brazilian Longitudinal Study of Adult Health (ELSA Brasil)
Introduction: Although inflammation plays a crucial role in coronary atherosclerosis, the association between inflammation and coronary artery calcium (CAC) is controversial. GlycA is a composite biomarker of acute phase glycoproteins that constitutes a broader measure of inflammation.
Hypothesis: Serum GlycA is associated with CAC above and beyond hsCRP.
Methods: We addressed the cross-sectional association of GlycA with CAC in 3783 individuals free of cardiovascular/chronic inflammatory disease and not taking statins at baseline of ELSA-Brasil. The GlycA nuclear magnetic resonance signal was deconvoluted from serum lipoproteins, and CAC was measured by computed tomography. We ran pairwise logistic regression for CAC >0 in 4 groups based on hsCRP and GlycA below (L) or above (H) median, where L hsCRP/ L GlycA was the reference group. Models were adjusted by demographic and lifestyle habits, family CAD history, body mass index (BMI) or, alternatively, waist circumference (WC).
Results: Increasing GlycA quartiles had more women, obesity, smokers, metabolic syndrome and less active persons. In age, sex and race analysis, H GlycA/ H hsCRP and H GlycA/ L hsCRP group had higher CAC odds ratios (1.49 [95%CI 1.15, 1.92, respectively]; 1.61 [95%CI 1.30, 1.98]), but not H hsCRP/ L GlycA group 1.14 (95%CI 0.87, 1.49). Results held in the fully adjusted model, but H GlycA/ H hsCRP and H GlycA/ L hsCRP effect sizes attenuated after adjustment for BMI, 1.43 [95%CI 1.14, 1.80] and 1.43 [95%CI 1.10, 1.87, respectively ](figure). For WC adjustment, instead of BMI, results were similar.
Conclusions: GlycA is associated with CAC in otherwise healthy individuals above and beyond hsCRP and it may better reflect the relationship between chronic inflammation and CAD.
Author Disclosures: P.H. Harada: None. M.S. Bittencourt: None. K. Nasir: Consultant/Advisory Board; Modest; Regeneron, Quest Diagnostic. M.J. Blaha: None. S.R. Jones: None. P.P. Toth: Speakers Bureau; Modest; Kowa, Novartis, Sanofi-Aventis. Consultant/Advisory Board; Modest; Merck, Regeneron, Sanofi-Aventis. Speakers Bureau; Significant; Amarin, Amgen, Merck, Regeneron. Consultant/Advisory Board; Significant; Amgen, Kowa, Regeneron, Merck. I.M. Benseñor: None. P.A. Lotufo: None.
- © 2016 by American Heart Association, Inc.